Why is ehlers danlos syndrome bad

Overview

Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders first described by physicians Edvard Ehlers in 1901 and Henri-Alexandre Danlos in 1908. The conditions affect collagen production and structure, leading to hypermobile joints, stretchy skin, and tissue fragility. There are 13 recognized subtypes, with hypermobile EDS being most common (affecting about 80% of cases) and vascular EDS being most severe. The 2017 International Classification recognized these distinct types, replacing older systems. Diagnosis typically involves clinical evaluation using the 2017 criteria, genetic testing for some subtypes, and assessment of family history. The conditions are genetic, usually inherited in an autosomal dominant pattern, though some rare forms follow autosomal recessive inheritance. Prevalence estimates vary, but most studies suggest 1 in 5,000 people have some form of EDS, with symptoms often appearing in childhood but diagnosis frequently delayed until adulthood.

How It Works

EDS results from genetic mutations affecting collagen synthesis, structure, or processing. Collagen is the body's main structural protein, providing strength and elasticity to skin, joints, blood vessels, and organs. In EDS, defects in genes like COL5A1, COL5A2, COL3A1, or TNXB disrupt collagen formation. For hypermobile EDS, the exact genetic cause remains unknown in most cases, though it involves connective tissue abnormalities. The defective collagen leads to joint hypermobility (excessive range of motion), allowing joints to dislocate or subluxate easily with minimal force. Skin becomes hyperextensible and fragile, bruising and tearing easily. In vascular EDS, mutations in COL3A1 weaken blood vessels and hollow organs, creating life-threatening rupture risks. The condition follows Mendelian inheritance patterns, with most types showing autosomal dominant transmission where one copy of the mutated gene from either parent causes the disorder.

Why It Matters

EDS matters because it causes debilitating daily challenges: chronic pain affects 90% of patients, joint instability limits mobility, and fatigue disrupts work and school. Many require assistive devices like braces or wheelchairs. The condition increases healthcare costs significantly, with patients averaging more specialist visits and hospitalizations. Vascular EDS carries mortality risks from arterial or organ rupture. Beyond physical effects, EDS impacts mental health, with higher rates of anxiety and depression. Awareness matters because early diagnosis improves management, yet diagnosis often takes decades. Research continues for better treatments, as current approaches focus on symptom management rather than cure.